{"preliminary_commentary":{"by_channel":{"x_thread":15,"youtube":8,"podcast":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05633602\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"Pragmatica-Lung","nct_id":"NCT05633602","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pragmatica-lung-nct05633602. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive chemotherapy per standard of care on study.","label":"ARM A (standard of care chemotherapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive ramucirumab IV and pembrolizumab IV on study.","label":"ARM B (ramucirumab, pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","Eli Lilly and Company","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2028-03-15","type":"ESTIMATED"},"conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":{"count":838,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Chemotherapy","otherNames":["Chemo","Chemotherapy (NOS)","Chemotherapy, Cancer, General"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda","Lambrolizumab","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Ramucirumab","otherNames":["Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B","Cyramza","IMC-1121B","LY3009806"],"type":"BIOLOGICAL"}],"last_update":"2026-04-17","lead_sponsor":"SWOG Cancer Research Network","official_title":"Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-11-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From date of randomization to date of death due to any cause, assessed up to 3 years"}],"references":[],"start_date":{"date":"2023-03-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","url":"https://clinicaltrials.gov/study/NCT05633602"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pragmatica-lung-nct05633602"}